Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

BERLIN (Reuters) -Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

"Today we're proud to announce that we're joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes." The company says it will ...

Roche said. Zealand is currently testing petrelintide in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs known as the long ...

The new trial investigated the role of the Pro version of the mySugr app, a digital diabetes logbook which Roche acquired along with its developer in 2017 and – in a defining moment for digital ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...